DALLAS, Jan. 18, 2022 /PRNewswire/ -- Lantern Pharma
(NASDAQ: LTRN), a clinical stage biopharmaceutical company using
its proprietary RADR® artificial intelligence ("A.I.")
platform to transform the cost, pace, and timeline of oncology drug
discovery and development, today announced a collaboration and
research agreement with The Danish Cancer Society Research Center
(DCRC) to support clinical development of Lantern's acylfulvene
class drug candidates, LP-100 and LP-184, as well as the
development of improved diagnostic methods to identify nucleotide
excision repair (NER) deficient tumors. LP-100 and LP-184 have both
shown synthetically lethal impact in tumors that are lacking NER
capabilities. The DCRC is a cancer research institute within the
Danish Cancer Society. The Danish Cancer Society is Denmark's largest non-government organization
and dedicates more than 60% of its budget to research, with the
remainder shared between prevention and patient support
initiatives. Lantern expects the data, genomic signatures and
biological models generated from this collaboration to add millions
of data points to RADR® and help accelerate the
development of new indications for LP-100 and LP-184. This
collaboration, together with the growing power of the
RADR® platform, can potentially uncover new drug
combinations using LP-100 and LP-184 for cancer treatments at a
fraction of the cost of traditional drug development.
![Lantern Pharma (LTRN) Logo (PRNewsfoto/Lantern Pharma) Lantern Pharma (LTRN) Logo (PRNewsfoto/Lantern Pharma)](https://mma.prnewswire.com/media/1216507/Lantern_Pharma_Logo.jpg)
The overall aim of the collaboration is to determine the most
promising patient populations for future LP-100 (irofulven) and
LP-184 therapy. The collaboration will focus on developing improved
diagnostic tools to detect NER deficiency patient profiles more
accurately. The research study conducted as part of the
collaboration will use expanded mutational signature-based analyses
to achieve this objective. The study will include a comprehensive
analysis of breast, ovarian, prostate, lung, kidney, bladder,
stomach, pancreatic and esophageal cancer. This collaboration will
help determine how many patients and which patients can benefit for
targeting NER deficiency and also help assess the overall market
size for both LP-100 and LP-184 across multiple solid tumors.
"Inherent DNA repair deficiencies characterize a subset of many
of our common tumor types and are increasingly relevant as markers
of therapeutic responses. The focus on defining NER deficiencies as
a potential marker for irofulven use is in line with our strategies
on drug repurposing as well as personalized oncology," says Mef
Nilbert, medical oncologist and research director at the DCRC.
The collaboration research will be led by Dr. Zoltan Szallasi,
MD as principal investigator at DCRC. Dr. Szallasi serves
joint appointments as Group Leader of the Translational Cancer
Genomics department at DCRC and as Faculty, Computational Health
Informatics Program (CHIP) and Assistant Professor of Pediatrics at
Boston Children's Hospital affiliated with Harvard Medical School.
"Through our breakthrough approach of collaborating with
internationally recognized research centers such as DCRC, we are
able to leverage and grow our proprietary RADR® A.I.
platform with millions of additional data points to further our
ability to rapidly discover biomarker signatures aimed at helping
identify patients more likely to respond to cancer therapies, which
we believe will significantly reduce development timelines and cost
of treatment," commented Panna
Sharma, CEO and President of Lantern Pharma Inc. "We are
assembling a growing body of data supporting LP-184 and LP-100's
synthetic lethality to tumor cells with either NER or HR
deficiency, and our collaboration with DCRC will further accelerate
our path to clinical trials as well as provide opportunities for
new trials and additional targeted indications."
LP-184 is a DNA-damaging small molecule drug candidate currently
in preclinical development for certain genomically defined solid
tumors, including pancreatic cancer and glioblastoma. As a
next-generation acylfulvene class agent that preferentially damages
DNA in cancer cells overexpressing certain biomarkers, LP-184 has
the potential to be used as both monotherapy as well as a
synergistic agent in combination with other drugs. LP-184 has been
granted Orphan Drug Designation by the U.S. Food and Drug
Administration for the treatment of malignant gliomas, as well as
pancreatic cancer.
LP-100 exploits cancer cells' deficiency in DNA repair
mechanisms. LP-100 has the potential to be an important compound —
either as monotherapy or in combination — for several challenging
cancers that are impacting patients globally. LP-100 is in an
existing genomic-signature guided phase 2 clinical trial in
Denmark for patients with
metastatic castration resistant prostate cancer (mCRPC). 9 patients
(out of a targeted enrollment of 27) have been treated in the
trial. The median overall survival (OS) for the initial group of 9
patients has been approximately 12.5 months, which is an
improvement over other similar fourth-line treatment regimens for
mCRPC.
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is
a clinical-stage oncology-focused biopharmaceutical company
leveraging its proprietary RADR® A.I. platform and
machine learning to discover biomarker signatures that identify
patients most likely to respond to its pipeline of genomically
targeted therapeutics. Lantern is currently developing four drug
candidates and an ADC program across eight disclosed tumor targets,
including two phase 2 programs. By targeting drugs to patients
whose genomic profile identifies them as having the highest
probability of benefiting from the drug, Lantern's approach
represents the potential to deliver best-in-class outcomes. More
information is available at: www.lanternpharma.com and Twitter
@lanternpharma.
About RADR®
RADR®, or Response
Algorithm for Drug Positioning & Rescue,
is Lantern's proprietary integrated A.I. platform for large-scale
biomarker and drug-tumor interaction data analytics that leverages
machine-learning. RADR® is used to provide
mechanistic insights about drug-tumor interactions, predict the
potential response of cancer types and subtypes to existing drugs
and drug candidates, and uncover patient groups that may respond to
potential therapies being developed by Lantern and its
collaborators.
Forward-looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements include, among other things, statements relating to:
future events or our future financial performance; the potential
advantages of our RADR® platform in identifying drug
candidates and patient populations that are likely to respond to a
drug candidate; our strategic plans to advance the development of
our drug candidates and antibody drug conjugate (ADC) development
program; estimates regarding the development timing for our drug
candidates and ADC development program; our research and
development efforts of our internal drug discovery programs and the
utilization of our RADR® platform to streamline the
drug development process; our intention to leverage artificial
intelligence, machine learning and genomic data to streamline and
transform the pace, risk and cost of oncology drug discovery and
development and to identify patient populations that would likely
respond to a drug candidate; estimates regarding potential markets
and potential market sizes; sales estimates for our drug candidates
and our plans to discover and develop drug candidates and to
maximize their commercial potential by advancing such drug
candidates ourselves or in collaboration with others. Any
statements that are not statements of historical fact (including,
without limitation, statements that use words such as "anticipate,"
"believe," "contemplate," "could," "estimate," "expect," "intend,"
"seek," "may," "might," "plan," "potential," "predict," "project,"
"target," "objective," "aim," "upcoming," "should," "will,"
"would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of our
collaborators may not be successful, (iii) the risk that none of
our product candidates has received FDA marketing approval, and we
may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for our product
candidates, (iv) the risk that no drug product based on our
proprietary RADR A.I. platform has received FDA marketing approval
or otherwise been incorporated into a commercial product, and (v)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and
Exchange Commission on March 10,
2021. You may access our Annual Report on Form 10-K for the
year ended December 31, 2020 under
the investor SEC filings tab of our website at
www.lanternpharma.com or on the SEC's website at www.sec.gov.
Given these risks and uncertainties, we can give no assurances that
our forward-looking statements will prove to be accurate, or that
any other results or events projected or contemplated by our
forward-looking statements will in fact occur, and we caution
investors not to place undue reliance on these statements. All
forward-looking statements in this press release represent our
judgment as of the date hereof, and, except as otherwise required
by law, we disclaim any obligation to update any forward-looking
statements to conform the statement to actual results or changes in
our expectations.
CONTACT
Investor Relations
Dave Gentry, RedChip Companies
IR@lanternpharma.com
1-800-733-2447
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-announces-collaboration--research-agreement-with-the-danish-cancer-society-research-center-to-support-clinical-development-of-drug-candidates-lp-100-and-lp-184-in-solid-tumors-301462613.html
SOURCE Lantern Pharma